ER+/ HER2 -ve Breast Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

September 13 20:35 2022
ER+/ HER2 -ve Breast Cancer Pipeline Assessment | In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 40+ key pharma and biotech companies are working on 50+ pipeline drugs in the ER+/ HER2 -ve Breast Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

ER+/ HER2 -ve Breast Cancer Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the ER+/ HER2 -ve Breast Cancer Market. 

The ER+/ HER2 -ve Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

ER+ HER2 -ve Breast Cancer Pipeline Analysis

ER+/ HER2 -ve Breast Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the ER+/ HER2 -ve Breast Cancer Treatment.

  • ER+/ HER2 -ve Breast Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report –

ER+/ HER2 -ve Breast Cancer Market Outlook

As per DelveInsight, the ER-positive/HER2-negative Breast Cancer market size was found to be USD 5,237.2 Million in 2017 in the 7MM, which is expected to grow in the coming years at an immense pace. The ER-positive/HER2-negative Breast Cancer Market Size is anticipated to increase owing to the rising incident population of ER+/HER2-ve Breast Cancer patients and the expected entry of premium price assets by major pharma and biotech giants.

DelveInsight’s Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I/II and Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

ER+/ HER2 -ve Breast Cancer Treatment Landscape

Conventionally, endocrine therapies are recommended for ER-Positive breast cancer as first-line treatment management options. If ET does not respond well, then chemotherapy is suggested by the oncologist.

Several key companies are actively working in the therapeutics market to provide better treatment options and overcome the existing challenges in the ER+/ HER2 -ve Breast Cancer Therapeutics segment.

ER+/ HER2 -ve Breast Cancer Therapeutics Outlook 

As per DelveInsight’s assessment, there are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. Currently, Astrazeneca has its ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage of clinical development. 

Some of the key companies in the ER+/ HER2 -ve Breast Cancer Therapeutics Market include:

Jiangsu HengRui Medicine, Odonate Therapeutics, Merck Sharp and Dohme, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Pharmacia and Upjohn Company, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merrimack Pharmaceuticals, Takeda Pharmaceuticals, Eagle Pharmaceuticals, Bayer, BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine. and many others.

ER+/ HER2 -ve Breast Cancer Therapies covered in the report include:

Pembrolizumab, Sapanisertib, GSK525762, Radium-223 dichloride, Entinostat, Venclexta, Ipatasertib, Sacituzumab govitecan, Elacestrant (RAD1901), Tesetaxel, SHR6390, AZD9833, BGB-290, and many others.

Further product details are provided in the report. Download the report to get more understanding of the emerging therapies and key companies operating in the market:


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. ER+/ HER2 -ve Breast Cancer Current Treatment Patterns

4. ER+/ HER2 -ve Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. ER+/ HER2 -ve Breast Cancer Late Stage Products (Phase-III)

7. ER+/ HER2 -ve Breast Cancer Mid-Stage Products (Phase-II)

8. ER+/ HER2 -ve Breast Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. ER+/ HER2 -ve Breast Cancer Discontinued Products

13. ER+/ HER2 -ve Breast Cancer Product Profiles

14. Key Companies in the ER+/ HER2 -ve Breast Cancer Market

15. Key Products in the ER+/ HER2 -ve Breast Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. ER+/ HER2 -ve Breast Cancer Unmet Needs

18. ER+/ HER2 -ve Breast Cancer Future Perspectives

19. ER+/ HER2 -ve Breast Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Diabetic Retinopathy Market
“Diabetic Retinopathy Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Diabetic Retinopathy Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States